The Global Diabetes Drugs Market is expected to reach US$ 78,261.7 mn by 2026 owing to rising prevalence of diabetes the world over. Key insights into this growing market have been shared by Fortune Business Insights in its report, titled “Diabetes Drugs Market Size, Share and Global Trend By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), Diabetes Type (Type 1, Type 2), Route of Administration (Oral, Subcutaneous, Intravenous), Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) & Geography Forecast till 2026”.
Get PDF Brochure of Diabetes Drugs Market: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetes-drugs-market-100570
The report comprehensively analyses the major factors that will influence the growth of the market. Diabetes is a chronic disease in which a person’s blood sugar or blood glucose gets too high. This glucose gets absorbed in the body through a hormone called insulin which is made in the pancreas. Insulin helps glucose enter the body’s cells, which, in turn, give the body energy to function.
Some of the Main Key Players Covered in the Diabetes Drugs Market Report
- Johnson & Johnson
- Bayer Pharmaceuticals
- Novo Nordisk
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim
Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570
Rising Number of Type 2 Diabetes Cases to Fuel the Market
Diabetes has various forms and the most prevalent ones include Type 1 (body fails to make any insulin), Type 2 (body does not make enough insulin), gestational (develops in pregnant women), and monogenic (rare genetic form of diabetes). Type 2 diabetes is the most common form of diabetes as it develops during middle age. The global diabetes drugs market is expected to grow considerably as Type 2 diabetes becomes even more widespread. Increasing sedentary lifestyle, rising stress levels, lack of exercise leading to obesity, and unhealthy food habits are the factors cited for the growth of the market.
North America Expected to Dominate the Market
North America is expected to hold a large chunk of the market share in the forecast period. This evaluation is based on the region’s revenue generation of USD 23,965.5 million in 2018. Moreover, rising prevalence of diabetes in the US is encouraging companies to develop novel and affordable drugs for the patients.
Growing awareness among the people regarding diabetes and anti-diabetic drugs in North America will aid growth of the global diabetes drugs market. North America is expected to be followed by Europe in terms of market share and revenue generation during the forecast period.
When the body does not make enough insulin or fails to make any insulin at all, a person becomes diabetic. The disease has no cure and can cause major health problems with age. Diabetes drugs are the medication that an affected person has to consume to regulate her glucose levels.
More Trending Topics from Fortune Business Insights:
Protease Inhibitors Market Top Players, Future Growth, Statistics, Size, Share Forecast 2026
Mobility Devices Market to Witness High Demand, Increasing cases of Diseases and Disabilities Will Aid Growth | Fortune Business Insights
Artificial Intelligence in Healthcare Market Growth, Global Share by Top Key Vendors | Intel Corporation, IBM Corporation, Microsoft, Google, Inc., GENERAL ELECTRIC, and more Forecast to 2026